Automated Cell Counters Market

Automated Cell Counters Market Size (2023 to 2028)

As per our analysis report, the global automated cell counters market is expected to reach USD 8.94 billion by 2028 from USD 6.59 billion in 2023, growing at a compound annual growth rate (CAGR) of 6.4% during the forecast period.

MARKET DRIVERS:

Automated cell counters are the medical devices that are used in life science labs and research institutes to count cells of animals, plants, bacteria, and humans automatically. They work on the principles of electrical impedance, image analysis, and light scattering. The increasing prevalence of several chronic ailments like autoimmune diseases, cancers, etc., is the primary factor driving the global automated cell counters market. Also, the spike in the worldwide elderly population that is easily prone to age-specific diseases and that requires the detection of underlying problems in the cells is another factor driving this business growth. The recent developments in the biotechnology and biopharmaceutical fields are driving the adoption of automated cell counters in applications like cell line development, cell culture monitoring, and so on. Some of the prominent developments in the healthcare sector like immunotherapy, regenerative medicine, and quick blood analysis use cell counting for precise results. Similarly, the rising adoption of point-care diagnostics to offer accurate outcomes in a short period is increasing their demand in the medical sector. The growth in the implementation of novel technologies like artificial intelligence, automation, 3D imaging, and robotics in pharmaceutical and healthcare industries is also boosting this market. In addition, the funds and grants offered by government and private enterprises for research and development activities are creating a positive outlook for the automated cell counters market. The surge in interest among people to spend money on diagnostics to ensure optimum health is promoting diagnostic centers and research centers, increasing demand in the global automated cell counters market. Moreover, the reduced labor costs and rising partnerships within the healthcare, diagnostic centers, and research centers to offer advanced therapeutic procedures like stem cell analysis and regenerative medicine are likely to create numerous opportunities for the automated cell counters market in the coming years.

MARKET RESTRAINTS:

Although there is a huge scope in the healthcare setting, automated cell counters still face some challenges that have to be addressed. The upfront cost for the development and production of these cell counters is comparatively huge, which is acting as a limitation for several new players to enter the automated cell counters market. In addition, the automated cell counters require constant maintenance to avoid any discrepancies in the outcomes, resulting in additional losses. Besides, the lack of properly trained staff to handle these cell counters in laboratories and research centers is acting negatively for the business growth. Technical challenges like integration with existing instruments and information systems, variations in size, type, and functionality of cells, and the need for upgraded models are also hampering sales in the automated cell counters market. The handling and interpretation of huge data collected by these cell counters along with the risks associated with cross-contamination can be a restraint to the market players. Moreover, the strict regulatory compliances related to the safety and quality of these devices coupled with the lack of advanced features in some of the existing models also pose a threat to the global automated cell counters market.

Impact of COVID-19 on the Automated Cell Counters Market:

The COVID-19 pandemic had a mixed impact on the global automated cell counters market. The immediate challenge to address COVID cases negatively impacted to the diagnostics procedures, resulting in either cancellation or postponement. The lockdown restrictions resulted in supply chain disruptions, leading to transportation and distribution challenges for the manufacturers. The shutdown of several companies led to the halt of research and development activities and a pause in the creation of new models. In addition, the decreased budget and expenditures to fight the spread of the pandemic further limited the production processes. Also, the temporary shutdowns and contactless conditions constrained patient interactions and clinical trials. All healthcare companies focussed mainly on COVID-19, affecting the funds and grants for the automated cell counters. On the other hand, the increased emphasis on health and the detection of diseases in the early stages is creating a positive outlook for medical diagnostics. During the pandemic, several chronic ailments were identified among the patients, paving the way for the use of cell counters in healthcare settings. Nevertheless, the trend of home sample collections and improved insurance services are likely to boost the automated cell counters market in the future.

REPORT COVERAGE:

This research report on the pain management therapeutics market has been segmented and sub-segmented based on the type, application, end-use, and region.

Automated Cell Counters Market – By Type:

• Hematology Analyzers
• Flow Cytometers
• Fluorescence Image-based
• Coulter Counter
• Spectrophotometers
• Consumables & Accessories

The spectrophotometers segment accounted for a significant share of the global market as it is the most prevalent device in the early identification of body ailments. The increasing research and development activities to formulate new drugs, adoption in bimolecular analysis, and surge in clinical diagnostics are fuelling this segment’s growth.

The fluorescence image-based cell counters are also finding huge demand in the diagnostics of infections related to urine, kidneys, blood glucose, and others. Similarly, the coulter counter segment is expected to record considerable growth in the following years because of the accurate results offered by these counters in clinical diagnosis. Nonetheless, the hematology analyzers are also touted to witness huge growth in the future owing to the need for tests like complete blood count as a basis for disease detection and the surge in the number of cases related to anemia, thalassemia, leukemia, and lymphoma.

Automated Cell Counters Market – By Application:

• Medical Diagnostics
• Cancer Research
• Drug Discovery
• Immunology
• Virology
• Others

Medical diagnostics applications registered the dominant portion of the global automated cell counters market and are likely to continue their dominion over the outlook period. The spike in the number of blood cell analyses to treat several blood-related diseases along with the government funds to support novel methods like stem cell analysis and regenerative medicine are supporting growth in this segment.

Automated Cell Counters Market – By End-Use:

• Hospitals & Diagnostic Centers
• Research Institutes
• Pharmaceutical & Biotechnology Companies

The hospitals & diagnostic centers recorded the majority share of the automated cell counters market. The surge in healthcare expenses, investments to improve infrastructure, and a one-stop solution for multiple diagnostics are boosting sales in this segment. The scalable and affordable options offered by the hospitals are also increasing their demand among the patients.

Automated Cell Counters Market - By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

North America recorded the highest share of the global automated cell counters market. The United States of America is the leading nation in this area. The advanced healthcare infrastructure and government-supported research institutes are fuelling the business growth in this area. The surge in demand for early diagnostic procedures and the rising prevalence of chronic diseases with unhealthy lifestyles are promoting diagnostic procedures in this region. Moreover, the flourishing biotechnology industry, drug discovery, and augmented clinical trials are likely to support the growth of automated cell counters in this area.

Asia Pacific is estimated to expand at the highest growth rate in this market over the foreseen period because of the advances in healthcare technologies and increasing investment from public and private sectors in clinical diagnostics. In addition, the trend of medical tourism and the affordability of various diagnostic procedures in Asian countries is encouraging more patients globally to avail of these services. Moreover, the mounting population and improving healthcare spending of consumers are anticipated to drive market growth in the APAC nations. China and India are leading nations in the Asia Pacific region.

Europe is also a significant market for automated cell counters owing to the growing adaptation of these counters to address medical staff shortages and increased investments in biopharma and stem cell procedures. The escalating demand for genomics, proteomics, and advanced medicine formulations also promotes the automated cell counters market in this locale.

Latin America registered a smaller portion of the global automated cell counters market. However, the mushrooming need for advanced therapeutic conditions, the spike in medical investments, and augmented research and development activities are likely to create lucrative opportunities in this locale.

The Middle East and Africa is also an emerging player in the automated cell counters market. Recently, nations in this region started focusing on modernizing the healthcare and research infrastructure, which can offer huge growth scope for this regional market in the future.

KEY MARKET MANUFACTURERS:

Merck KGaA, Becton, Dickinson & Co., Olympus Corporation, Abbott Laboratories, F. Hoffman-La Roche AG, Sysmex Corporation, Agilent Technologies, Thermo Fischer Scientific, Bio-Rad Laboratories, Inc., Beckman Coulter, Nanoentek, Chemometec A/S, Nexcelom Bioscience LLC, Countstar Inc., Eppendorf, PerkinElmer Inc., Logos Biosystems, Tecan, Corning Inc., Biotek Instruments, Inc., and Alere Inc.

Recent Market Happenings:

• In February 2023, DeNovix announced a free offering of Green CellDrop automated cell counter to celebrate its Sustainable Laboratory Product of the Year award from SelectScience. The CellDrop counter uses the patented technology of DirectPipette to reduce the number of slides in the cell counting process, reducing the usage of almost 33,000 kilograms of plastic.
• In November 2023, Beckman Coulter Life Sciences, a US-based laboratory automation and innovation company obtained approval from the Food Drug and Administration (FDA) to launch its sales of the AQUIOUS STEM System that offers assistance in hematopoietic stem cell counting.